Related Experiment Video
Updated: Apr 21, 2026
07:44
An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
28.7K
Leptin antagonism improves Rett syndrome phenotype in symptomatic Mecp2-deficient mice
Yasmine Belaïdouni1, Diabe Diabira1, Pascal Salin2
1INMED, INSERM, Aix Marseille University, Marseille, France.
Summary
Reducing leptin signaling alleviates Rett syndrome (RTT) symptoms in mice. This discovery highlights leptin as a therapeutic target for RTT, a severe neurodevelopmental disorder.
Area of Science:
- Neuroscience
- Genetics
- Endocrinology
Background:
- Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder.
- Mutations in MECP2 cause RTT.
- Elevated leptin levels are observed in RTT patients and models, but their role is unclear.
Purpose of the Study:
- To investigate the role of leptin signaling in RTT pathophysiology.
- To determine if reducing leptin signaling can alleviate RTT-like phenotypes.
Main Methods:
- Used Mecp2-deficient mice (RTT model).
- Administered pharmacological and genetic interventions to reduce leptin signaling.
- Assessed general health, weight, breathing, and locomotor functions.
- Analyzed neuronal function, including excitatory/inhibitory balance and synaptic plasticity.
Main Results:
- Reducing leptin signaling significantly alleviated RTT-like phenotypes in male mice.
- Interventions preserved general health, prevented weight loss, and improved motor and respiratory functions.
- Neuronal level improvements included restored brain excitatory/inhibitory balance and rescued hippocampal synaptic plasticity.
- In female mice, delaying leptin rise postponed symptom progression.
Conclusions:
- Leptin signaling is a key contributor to RTT pathophysiology.
- Targeting leptin signaling represents a promising therapeutic strategy for RTT.
